Advantage Alpha Capital Partners’s ADMA Biologics ADMA Stock Holding History

Advantage Alpha Capital Partners’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-33,943	Closed	-$498K	–	3
2025 Q3	$498K	Sell	33,943 -9,875	-23%	-$169K	0.15%	105
2025 Q2	$798K	Sell	43,818 -62,257	-59%	-$1.27M	0.22%	92
2025 Q1	$2.1M	Buy	106,075 +36,893	+53%	+$638K	0.52%	77
2024 Q4	$1.19M	Sell	69,182 -18,209	-21%	-$343K	0.28%	90
2024 Q3	$1.75M	Sell	87,391 -66,160	-43%	-$1.03M	0.4%	89
2024 Q2	$1.72M	Sell	153,551 -30,915	-17%	-$259K	0.37%	82
2024 Q1	$1.22M	Buy	+184,466	New	+$1.01M	0.23%	91

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SHCM

Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Advantage Alpha Capital Partners's ADMA Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 33,943 shares — an estimated $498K sold.

Advantage Alpha Capital Partners first reported a position in ADMA in Q1 2024 and held it in 7 quarters. The position peaked at $2.1M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

Advantage Alpha Capital Partners reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
Advantage Alpha Capital Partners sold 33,943 ADMA Biologics shares in Q4 2025, an estimated $498K.
Advantage Alpha Capital Partners first reported a position in ADMA Biologics in Q1 2024 and held it in 7 quarters.
Advantage Alpha Capital Partners's ADMA Biologics position peaked at $2.1M in Q1 2025.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.